Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
34 Results for "
SMARCA4 protein
" in MedChemExpress (MCE) Product Catalog:
Products (34)
34 Results for "SMARCA4 protein" in MCE Product Catalog:
2
2 Cited Publications
Target:
Research Areas:
FHT-1015 is a selective SMARCA4 (IC50 = 4 nM) and SMARCA2 (IC50 = 5 nM) (also known as BRG1 and BRM) inhibitor. FH-1015 is an allosteric inhibitor that causes conformation change in the BRG1/BRM protein upon interaction with an allosteric site, inhibiting ATPase activity. FH-1015 interferes with tumor cell growth and migration. FH-1015 can be studied in research for uveal melanoma and hematologic cancer .
1
1 Cited Publications
Synonyms: VHL ligand 3; E3 ligase Ligand 19
Target:
Research Areas:
VH032-cyclopropane-F is the VH032-based VHL ligand. VH032-cyclopropane-F can be connected to the ligand for protein (e.g., SMARCA BD ligand) by a linker to form PROTACs (e.g., PROTAC 1). PROTAC 1 is a partial degrader of SMARCA2 and SMARCA4 .
Cat. No.: HY-173351
CAS No.: 2901806-51-5
Target:
Research Areas:
G-6599 is a covalent molecular glue degrader targeting SMARCA2/SMARCA4, with DC50 values of 0.017 nM and 0.057 nM against SMARCA2 and SMARCA4 in SW1573 cells, respectively. G-6599 exhibits proteome selectivity for SMARCA2, SMARCA4, and PBRM1. G-6599 induces the assembly of the SMARCA2-FBXO22 ternary complex, enabling ubiquitination and proteasomal degradation of both proteins via the ubiquitin-proteasome pathway without the need for biotransformation. G-6599 shows antiproliferative effects in relevant cancer cell models. G-6599 can be used for research on androgen-dependent prostate cancer and SMARCA4-mutant non-small cell lung cancer .
Cat. No.: HY-170824
CAS No.: 3033586-31-8
Target:
Research Areas:
SMD-3236 is a SMARCA2 PROTAC degrader with a DC50 of 0.5 nM, a Dmax of 98%, and an IC50 of 42.2 nM against human SMARCA2. SMD-3236 induces proteasome- and ubiquitin-like modification-dependent degradation of SMARCA2 protein by binding to SMARCA2 and VHL-1. SMD-3236 inhibits the growth of SMARCA4-deficient cancer cells. SMD-3236 induces significant and persistent depletion of SMARCA2 in tumor tissues. SMD-3236 suppresses tumor growth in SMARCA4-deficient human cancer xenograft models. SMD-3236 can be used in research related to SMARCA4-deficient cancers such as melanoma, non-small cell lung cancer, and acute myeloid leukemia .
Cat. No.: HY-170817
CAS No.: 3033592-13-8
Research Areas:
SMI-1074, a SMARCA bromodomain inhibitor, is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC). SMI-1074 can be used for synthesis SMD-3236 (HY-170824) and SMD-1087 (HY-170828). SMI-1074 can be used for the research of smarca4-deficient cancers .
Cat. No.: HY-163152
CAS No.: 2378051-80-8
Target:
Research Areas:
PROTAC BRM degrader-1 is a VHL-recruiting PROTAC degrader that exhibits higher selectivity for the degradation of SMARCA2 (BRM) over its highly homologous protein SMARCA4 (BRG1). The KD values of PROTAC BRM degrader-1 for BRM and BRG1 are 72 nM and 108 nM, respectively. PROTAC BRM degrader-1 can be used in studies related to selective SMARCA2 degradation, SWI/SNF function, and SMARCA4-mutant non-small cell lung cancer .
Cat. No.: HY-170828
CAS No.: 3033586-04-5
Target:
Research Areas:
SMD-1087 is a VHL-recruiting SMARCA2 PROTAC degrader with a DC50 of 8 nM. SMD-1087 induces ubiquitination and degradation of SMARCA2 via the proteasome pathway. SMD-1087 reduces PBRM1 protein levels, inhibits the growth of SMARCA4-deficient cancer cells, and suppresses tumor growth in mouse xenograft models. SMD-1087 can be used for research on SMARCA4-deficient human cancers, including lung cancer and melanoma .
Cat. No.: HY-171774
CAS No.: 1997321-76-2
Research Areas:
PBRM1/SMARCA2,4-ligand-1 (Compound 4) is a Ligand for Target Protein for PROTAC that binds to PBRM1, SMARCA2, and SMARCA4. PBRM1/SMARCA2,4-ligand-1 is a potent SMARCA4 bromodomain inhibitor. PBRM1/SMARCA2,4-ligand-1 can be used to synthesize PROTAC AU-24118 (HY-163410) .
Cat. No.: HY-162745
CAS No.: 2568273-85-6
Target:
Research Areas:
PROTAC SMARCA2/4 degrader-42 is a SMARCA2 and SMARCA4 PROTAC degrader that induces protein ubiquitination and subsequent proteasomal degradation. PROTAC SMARCA2/4 degrader-42 can be used in cancer-related research .
Cat. No.: HY-159455
CAS No.: 2568523-81-7
Target:
Research Areas:
PROTAC SMARCA2/4-degrader-4 (Compound I-434) is a PROTAC degrader for catalytic subunit of the SWI/SNF complex SMARCA2 and SMARCA4. PROTAC SMARCA2/4-degrader-4 degrades SMARCA2 in MV411 and in A549 with DC50 <100 nM, degrades SMARCA4 in MV411 with DC50 <100 nM. (Pink: Ligand for target protein (HY-159472); Black: Linker (HY-159478); Blue: Ligand for E3 ligase (S,R,S)-AHPC (HY-125845))
Cat. No.: HY-159453
CAS No.: 2568277-76-7
Target:
Research Areas:
PROTAC SMARCA2/4 degrader-2 is a PROTAC degrader targeting SMARCA2 and SMARCA4, with a DC50 of < 100 nM for both proteins. PROTAC SMARCA2/4 degrader-2 induces ubiquitination and subsequent proteasome-mediated degradation of SMARCA2 and SMARCA4 proteins. PROTAC SMARCA2/4 degrader-2 can be used in cancer-related research .
Cat. No.: HY-163875
CAS No.: 2568277-48-3
SMARCA2 degrader-14 (compound I-408) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the DC50s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .
Cat. No.: HY-163876
CAS No.: 2568277-50-7
SMARCA2 degrader-15 (compound I-409) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the DC50s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .
Cat. No.: HY-162748
CAS No.: 2568276-44-6
Target:
Research Areas:
PROTAC SMARCA2/4 degrader-30 is a SMARCA2 and SMARCA4 PROTAC degrader. PROTAC SMARCA2/4 degrader-30 induces ubiquitination and proteasome-mediated degradation of proteins. PROTAC SMARCA2/4 degrader-30 is applicable for cancer-related research .
Cat. No.: HY-162834
CAS No.: 2375564-54-6
Target:
Research Areas:
PROTAC SMARCA2/4 degrader-27 is a VHL-recruiting PROTAC degrader targeting SMARCA2 and SMARCA4, derived from structure-guided modification of PROTAC SMARCA2/4 degrader-28 (HY-162835). PROTAC SMARCA2/4-degrader-27 forms a cooperative ternary complex with CRL2VHL E3 ligase to induce ubiquitination and degradation. PROTAC SMARCA2/4-degrader-27 induces a novel protein-protein interaction between VHL and SMARCA2/SMARCA4, thereby stabilizing ternary complex formation and promoting proteasomal degradation of target proteins. PROTAC SMARCA2/4-degrader-27 exhibits enhanced cell permeability and stronger ternary complex formation ability, leading to improved degradation activity. PROTAC SMARCA2/4-degrader-27 can be used in cancer-related research[1].
Cat. No.: HY-159452
CAS No.: 2568273-68-5
SMARCA2/4-degrader-1 (compound I-430) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the DC50s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .
Cat. No.: HY-159461
CAS No.: 2568507-15-1
Target:
Research Areas:
PROTAC SMARCA2/4 degrader-9 is a SMARCA2 and SMARCA4 PROTAC degrader. PROTAC SMARCA2/4 degrader-9 induces protein ubiquitination and subsequent proteasome-mediated degradation. PROTAC SMARCA2/4 degrader-9 can be used in cancer-related research .
Cat. No.: HY-162741
CAS No.: 2568276-36-6
PROTAC SMARCA2/4-degrader-33 (compound I-277) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the DC50s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .
Cat. No.: HY-163869
CAS No.: 2568273-64-1
PROTAC SMARCA2/4-degrader-16 (compound I-337) is a PROTAC degrader targeting SMARCA2 and SMARCA4; it degrades SMARCA2/4 proteins in A549 cells with the DC50s <100 nM, and the maximum degradation rate (Dmax%) >90 after 24 h of treatment .
Cat. No.: HY-163864
CAS No.: 2568276-71-9
Target:
Research Areas:
PROTAC SMARCA2/4 degrader-11 is a PROTAC degrader targeting SMARCA2 and SMARCA4. PROTAC SMARCA2/4 degrader-11 induces protein ubiquitination and subsequent proteasome-mediated degradation. PROTAC SMARCA2/4-degrader-11 can be used in cancer-related research .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
